



Arzerra® (ofatumumab) (Intravenous)

Document Number: IC-0208

Last Review Date: 04/04/2022

Date of Origin: 08/26/2014

Dates Reviewed: 03/2015, 05/2015, 08/2015, 11/2015, 02/2016, 05/2016, 08/2016, 11/2016, 02/2017, 05/2017, 08/2017, 11/2017, 02/2018, 05/2018, 04/2019, 04/2020, 04/2021, 04/2022

I. Length of Authorization ^{1,10}

Coverage will be provided for 6 months with renewal subject to the following:

- CLL/SLL (first-line) may be renewed to allow for a total of 12 cycles
- CLL/SLL (relapsed) may not be renewed (unless the provisions for extended treatment have been met)
- CLL/SLL (single agent subsequent therapy) may not be renewed (unless the provisions for extended treatment have been met)
- CLL/SLL (extended treatment) may be renewed to provide for a total of 2 years of therapy
- Waldenström’s Macroglobulinemia/Lymphoplasmacytic lymphoma may be renewed to allow for up to a total of 3 cycles

II. Dosing Limits

A. Quantity Limit (max daily dose) [NDC Unit]:

- Arzerra 100 mg/5 mL single-use vial: 3 vials Day 1
- Arzerra 1000 mg/50 mL single-use vial: 2 vials weekly x 7 doses, then 2 vials every 4 weeks, then 1 vial every 8 weeks for up to 24 months

B. Max Units (per dose and over time) [HCPCS Unit]:

CLL/SLL	<p>First-Line</p> <ul style="list-style-type: none"> ▪ 30 billable units on day 1 and 100 billable units on day 8; then ▪ 100 billable units every 28 days for up to 11 doses <p>Single agent subsequent therapy</p> <ul style="list-style-type: none"> ▪ 30 billable units on day 1; then ▪ 200 billable units weekly x 7 doses; then ▪ 200 billable units every 28 days x 4 doses <p>Relapsed</p> <ul style="list-style-type: none"> ▪ 30 billable units on day 1 and 100 billable units on day 8; then ▪ 100 billable units every 28 days for up to 5 doses <p>Extended Treatment</p> <ul style="list-style-type: none"> ▪ 30 billable units on day 1 and 100 billable units on day 8; then ▪ 100 billable units 7 weeks later and every 8 weeks thereafter
---------	---

Waldenström's Macroglobulinemia / Lymphoplasmacytic Lymphoma	<ul style="list-style-type: none">▪ 30 billable units on day 1; then▪ 200 billable units every 7 days x 4 doses
---	--

III. Initial Approval Criteria ¹

Coverage is provided in the following conditions:

- Patient is at least 18 years of age; **AND**

Universal Criteria ¹

- Patient has been screened for the presence of hepatitis B (HBV) infection (i.e., HBsAg and anti-HBc) prior to initiating therapy and patients with evidence of current or prior HBV infection will be monitored for HBV reactivation during treatment; **AND**
- Must not be administered concurrently with live vaccines; **AND**

Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) † Φ ¹⁻³

- Used as first-line therapy; **AND**
 - Used in combination with chlorambucil in patients considered inappropriate for fludarabine-based therapy (*Note: only applies to CLL*); **OR**
 - Used in combination with bendamustine ‡; **AND**
 - Patient does not have del(17p)/TP53 mutation (*patients ≥ 65 years, or younger patients with or without significant comorbidities; excluding use in frail patients [i.e., creatine clearance (CrCl) <70 mL/min]*); **OR**
- Used as subsequent therapy; **AND**
 - Used as a single agent; **OR**
 - Used in combination with fludarabine and cyclophosphamide (FC) for relapsed disease (*Note: only applies to CLL*); **OR**
- Used as extended treatment in patients with complete or partial response after at least 2 lines of therapy for recurrent or progressive disease (*Note: only applies to CLL*)

Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma ‡ ^{2,4}

- Used as a single agent OR as part of combination therapy; **AND**
- Patient is intolerant to rituximab; **AND**
 - Patient has previously failed primary therapy; **OR**
 - Patient has progressive or relapsed disease

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); Φ Orphan Drug

IV. Renewal Criteria ¹

Coverage may be renewed based on the following criteria:

- Patient continues to meet universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: Hepatitis B virus reactivation/infection, progressive multifocal leukoencephalopathy, severe infusion reactions, tumor lysis syndrome, cytopenias (neutropenia, anemia, and thrombocytopenia), etc.

V. Dosage/Administration ^{1,10}

Indication	Dose
CLL/SLL (First-line)	Administer 300 mg on Day 1, then 1,000 mg on Day 8, followed by 1,000 mg on Day 1 of subsequent 28-day cycles for a minimum of 3 cycles until best response or a maximum of 12 cycles
CLL/SLL (Single agent subsequent therapy)	Administer 300 mg on Day 1, followed 1 week later by 2,000 mg given weekly x 7 doses (infusions 2 through 8), followed 4 weeks later by 2,000 mg every 4 weeks for 4 doses (infusions 9 through 12) for a total of 12 doses
CLL/SLL (Relapsed)	Administer 300 mg on Day 1, then 1,000 mg on Day 8, followed by 1,000 mg on Day 1 of subsequent 28-day cycles for a maximum of 6 cycles
CLL/SLL (Extended treatment)	Administer 300 mg on Day 1, then 1,000 mg on Day 8, followed by 1,000 mg 7 weeks later and every 8 weeks thereafter for up to a maximum of 2 years
Waldenström's/ Lymphoplasmacytic lymphoma	<p>Cycle 1:</p> <ul style="list-style-type: none"> • Administer 300 mg on day 1, then 1,000 mg weekly for weeks 2 through 4; OR • Administer 300 mg on day 1, then 2,000 mg weekly for weeks 2 through 5. <p>Cycle 2-3:</p> <ul style="list-style-type: none"> • Patients with stable disease or a minor response at week 16 of cycle 1 are eligible to receive a re-dosing cycle of 300 mg on day 1, then 2,000 mg for weeks 2 through 5. • Patients responding to cycle 1 or the redosing cycle who developed disease progression within 36 months can receive treatment with 300 mg on day 1, then 2,000 mg for weeks 2 through 5.

VI. Billing Code/Availability Information

HCPCS Code:

- J9032 – Injection, ofatumumab, 10 mg; 1 billable unit = 10 mg

NDC:

- Arzerra 1000 mg/50 mL single-use vial: 00078-0690-xx
- Arzerra 100 mg/5 mL single-use vial: 00078-0669-xx

VII. References

1. Arzerra [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation, August 2016. Accessed March 2022.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) ofatumumab. National Comprehensive Cancer Network, 2022. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed March 2022.
3. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 2.2022. National Comprehensive Cancer Network, 2022. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed March 2022.
4. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma. Version 2.2022. National Comprehensive Cancer Network, 2022. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed March 2022.
5. Furman RR, Eradat H, DiRienzo CG, et al. A phase II trial of ofatumumab in subjects with Waldenstrom's macroglobulinemia. *Blood*. 2011;118:3701
6. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. *J Clin Oncol* 2010;28:1749-1755
7. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) B-Cell Lymphomas. Version 1.2022. National Comprehensive Cancer Network, 2022. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed March 2022.
8. Rosenbaum CA, Jung SH, Pitcher B, et al. Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance). *Br J Haematol*. 2019 Feb 5.
9. Van Imhoff GW, McMillan A, Matasar MJ et al. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. *J Clin Oncol* 2017;35 (5):544-551.

10. Furman RR, Eradat HA, DiRienzo CG, et al. Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. *Lancet Haematol.* 2017 Jan;4(1):e24-e34. doi: 10.1016/S2352-3026(16)30166-1. Epub 2016 Dec 1.
11. Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. *Lancet.* 2015 May 9;385(9980):1873-83. doi: 10.1016/S0140-6736(15)60027-7. Epub 2015 Apr 14.
12. Robak T, Warzocha K, Govind Babu K, et al. Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. *Leuk Lymphoma.* 2017 May;58(5):1084-1093. doi: 10.1080/10428194.2016.1233536. Epub 2016 Oct 12.
13. van Oers MH, Kuliczkowski K, Smolej L, et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. *Lancet Oncol.* 2015 Oct;16(13):1370-9. doi: 10.1016/S1470-2045(15)00143-6. Epub 2015 Sep 13.
14. Lemery SJ, Zhang J, Rothmann MD, et al. U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab. 10.1158/1078-0432.CCR-10-0570 Published September 2010.
15. Chen L, Shah R, Cwynarski K. et al. Ofatumumab is a feasible alternative anti-CD20 therapy in patients intolerant of rituximab. *Br J Haematol.* 2019 Feb;184(3):462-465. doi: 10.1111/bjh.15110. Epub 2018 Jan 24.

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
C83.00	Small cell B-cell lymphoma, unspecified site
C83.01	Small cell B-cell lymphoma, lymph nodes of head, face and neck
C83.02	Small cell B-cell lymphoma, intrathoracic lymph nodes
C83.03	Small cell B-cell lymphoma, intra-abdominal lymph nodes
C83.04	Small cell B-cell lymphoma, lymph nodes of axilla and upper limb
C83.05	Small cell B-cell lymphoma, lymph nodes of inguinal region and lower limb
C83.06	Small cell B-cell lymphoma, intrapelvic lymph nodes
C83.07	Small cell B-cell lymphoma, spleen
C83.08	Small cell B-cell lymphoma, lymph nodes of multiple sites
C83.09	Small cell B-cell lymphoma, extranodal and solid organ sites
C88.0	Waldenström macroglobulinemia
C91.10	Chronic lymphocytic leukemia of B-cell type not having achieved remission

ICD-10	ICD-10 Description
C91.12	Chronic lymphocytic leukemia of B-cell type in relapse

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Article (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCA/LCD): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC